ArticleNPJ science of food2025
Exploring similarities and differences in anti-atherosclerotic potential bioactives among Dendrobium species by UPLC-Q-Exactive Orbitrap MS.
Article in NPJ science of food, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- An integrated green strategy based on deep eutectic solvents and ultrasound for efficient polyphenol profiling and antioxidant evaluation of dendrobium officinale.Ultrasonics sonochemistry · 2026Article
- Revealing key antioxidant compounds and mechanisms in Fritillaria Bulbus by metabolomics and network pharmacology.NPJ science of food · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Atherosclerosis is a primary cause of cardiovascular disease, straining healthcare systems. Dendrobium officinale, a widely used food-medicine homology, has demonstrated anti-atherosclerotic (anti-AS) properties, with other species listed in pharmacopoeias exhibiting similar effects. However, their efficacy varies, and the impact of interspecies variations on compounds and mechanisms in Dendrobium's anti-AS effects remains unclear. This study aimed to explore the anti-AS compounds and mechanisms across various Dendrobium species. The chemical composition of D. fimbriatum, D. officinale, D. devonianum, D. gratiosissimum, and D. catenatum was analyzed using UPLC-Q-Exactive Orbitrap MS. Network pharmacology predicted the pharmacological basis and molecular mechanisms. Molecular docking experiments assessed the binding affinity of the identified compounds with target proteins. A total of 12 different and 65 common components were identified. Key therapeutic targets included SRC, STAT3, and PIK3CA, along with relevant signaling pathways linked to AS prevention. The study provides insights into interspecies differences in Dendrobium's anti-AS properties.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.